Addex Therapeutics Secures €4M Eurostars Grant for mGlu2 NAM Program in Neurocognitive Disorder
Portfolio Pulse from Benzinga Newsdesk
Addex Therapeutics (NASDAQ:ADXN) has led a consortium that has been awarded a €4 million Eurostars grant to support its mGlu2 receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder. The consortium includes Naason Science, BioAxis Research, Pharmidex Pharmaceutical Services, and Stichting Radboud Universiteit.
September 20, 2023 | 7:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The €4 million Eurostars grant awarded to Addex Therapeutics for its mGlu2 NAM program could potentially boost the company's research and development efforts.
The grant will provide financial support for Addex Therapeutics' mGlu2 NAM program, which could lead to advancements in the treatment of mild neurocognitive disorder. This could potentially increase the company's value and attractiveness to investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100